SCLC ClinicalImpact: New Tools and Expert Guidance for Integrating Immunotherapies

Review key data that support use of concurrent chemoradiotherapy with cisplatin plus etoposide as standard of care for LS-SCLC.

Benjamin Levy, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 30, 2020 Expired: November 29, 2021

Gain expert insight on the biologic rationale for using immune checkpoint inhibition for the treatment of ES-SCLC, including the potential for synergism between immunotherapy and platinum-based chemotherapy.

Mark A. Socinski, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 1, 2020 Expired: November 30, 2021

Watch this short video evaluating key clinical trial data supporting use of first-line immune checkpoint inhibitors plus chemotherapy in the treatment of newly diagnosed ES-SCLC.

Mark A. Socinski, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 1, 2020 Expired: November 30, 2021

Watch this short video discussing current best practices for treating a patient with newly diagnosed extensive-stage SCLC.

Benjamin Levy, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 9, 2020 Expired: December 8, 2021

View this short video evaluating the clinical trial data for second-line and third-line treatment options for relapsed ES-SCLC.

Benjamin Levy, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 1, 2020 Expired: November 30, 2021

Watch this short case-based video for an overview of the evolving systemic therapy options for the treatment of relapsed ES-SCLC.

Mark A. Socinski, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 5, 2021 Expired: February 4, 2022

Watch this short video on early recognition and management of immune-related adverse events from immunotherapy for the treatment of ES-SCLC in the context of a patient case.

Mark A. Socinski, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 5, 2021 Expired: February 4, 2022

Watch this short video to get up to date on the role of prophylactic cranial irradiation and consolidative thoracic radiotherapy in the treatment of ES-SCLC.

Benjamin Levy, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 2, 2021 Expired: February 1, 2022

Watch this short video to get up to date on the role of biomarkers in predicting benefit of immune checkpoint blockade during treatment of extensive-stage SCLC.

Benjamin Levy, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 1, 2021 Expired: January 31, 2022

Watch this short video for an expert review of key ongoing trials of immune checkpoint inhibitor combinations for SCLC to consider for your patients, including ADRIATIC and NRG-LU005 for limited-stage disease and SKYSCRAPER-02 for extensive-stage disease.

Mark A. Socinski, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 2, 2021 Expired: February 1, 2022